CVS Health Corporation (CVS) has agreed to acquire the entire outstanding shares of Aetna for a total consideration of $77bn.

The shareholders of the target company will be paid $145 a share in cash and issued 0.8378 CVS shares for each Aetna share held. The target company shareholders will hold 22% of the merged company, while the remaining will be held by the acquirer company shareholders.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The transaction will integrate the expertise of CVS and Aetna to redefine consumer healthcare experience and build a healthcare platform for individuals.

“NeuroSearch has announced its intention to be sold to a potential buyer in 2018.”

NeuroSearch has announced its intention to be sold to a potential buyer in 2018.

Based in Denmark, NeuroSearch is a biotechnology company involved in developing pharmaceuticals for the treatment of diseases and disorders.

The firm plans for voluntary liquidation in case it does not secure a satisfactory bid.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The net proceeds of liquidation are intended to be distributed to the shareholders.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now